Clinical trial
A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular…
NCT00136591 · Lymphoma Study Association, Other · Terminated
Key facts
| NCT number | NCT00136591 |
|---|---|
| Title | A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma |
| Official title | A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma |
| Lead sponsor | Lymphoma Study Association, Other |
| Collaborators | Janssen-Cilag International NV Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Follicular Lymphoma |
| Intervention type | Drug |
| Interventions | Bortezomib |
| Enrollment | 87 |
| Start date | Sep 1, 2005 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Aug 29, 2005 |
| Last update posted | Oct 26, 2010 |
| Countries | Belgium, France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: